交易 Immunome Inc - IMNM 差价合约
Immunome Inc (NASDAQ: IMNM) is a clinical-stage biopharma company developing antibody-based therapies targeting difficult-to-treat cancers and infectious diseases. Using its proprietary B cell discovery platform, the company is building a differentiated oncology pipeline. Immunome offers investors early-stage biotech exposure with platform-driven development optionality.最新股票文章

SpaceX上市首日收涨19%——IPO后如何交易SpaceX SPCX差价合约
SpaceX(SPCX)于2026年6月12日在纳斯达克首次上市,开盘报150美元,收盘报160.95美元,较135美元的IPO发行价上涨19.2%。
08:41, 16 六月 2026


